Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature

doi:10.12998/wjcc.v10.i33.12305

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 33

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2960)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

146

WORD

HTML

1536

Figures (1-2)

326

Sum=2042

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

253

Download

665

Sum=918

Nov 26, 2022 (publication date) through Dec 18, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Nov 26, 2022; 10(33): 12305-12312
Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12305

Full Size Figure Download Figure

Figure 2 The timeline of treatment and procedures. EGFR: Epidermal growth factor receptor.

Citation: Long XY, Zhang S, Tang LS, Li X, Liu JY. Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature. World J Clin Cases 2022; 10(33): 12305-12312
URL: https://www.wjgnet.com/2307-8960/full/v10/i33/12305.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i33.12305